☆ 4.6 Review

Neoadjuvant therapy for pancreatic cancer

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pathology

Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature

Michael J. Allen et al.

Summary: This study investigated the prevalence and genomic characteristics of NTRK fusions in pancreatic ductal adenocarcinoma (PDAC). Among 400 patients, 3 patients were found to have NTRK fusions. NTRK fusions are rare in PDAC but detection is vital for emerging therapeutic options.

JOURNAL OF CLINICAL PATHOLOGY (2023)

添加到收藏夹

Article Surgery

Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer

Thomas Hank et al.

Summary: This study aimed to investigate the outcome of conversion surgery in patients with metastatic pancreatic cancer and identify patients who may benefit from this approach. The findings showed that patients with complete pathological response of metastases after surgery had better survival rates, and adjuvant chemotherapy provided an additional survival advantage.

ANNALS OF SURGERY (2023)

添加到收藏夹

Article Surgery

Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival

Thilo Hackert et al.

Summary: This study evaluated the outcomes of pancreatic cancer surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). Surgery offers the only chance for cure in pancreatic cancer, and PVR is often performed for borderline or locally advanced tumors. The results showed that postoperative morbidity correlates with the reconstruction type, and when radical resection is achieved, thrombosis risk is outweighed by beneficial overall survival times of nearly 2 years.

ANNALS OF SURGERY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX , or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh et al.

Summary: The study compared the feasibility and efficacy of three different types of short-course neoadjuvant therapy with immediate surgery. The findings showed that neoadjuvant chemotherapy significantly prolonged survival, with gemcitabine plus capecitabine or FOLFIRINOX regimen demonstrating the best results.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Article Oncology

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group

T. Seufferlein et al.

Summary: This study aimed to evaluate the efficacy of perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that the preoperative chemotherapy group had a higher disease-free survival rate at 18 months compared to the adjuvant chemotherapy group.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Surgery

Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma Who Beats the Odds?

Oliver Strobel et al.

Summary: This study investigated the actual five-year survival rate of pancreatic ductal adenocarcinoma (PDAC) with a strategy of upfront surgery and adjuvant therapy. The results showed that the actual five-year survival rate for PDAC patients who underwent upfront surgery and adjuvant therapy was 18.8%. Tumor grading, number of positive lymph nodes, intraductal papillary mucinous neoplasia, and vascular resections were found to be independent factors associated with the five-year survival rate.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Oncology

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

Julia E. Douglas et al.

Summary: This article describes a platform clinical trial for pancreatic ductal adenocarcinoma (PDAC) using a Bayesian platform design. The trial aims to evaluate the effectiveness of multiple experimental arms compared to a control arm in PDAC patients. Patients are divided into different cohorts based on clinical stage and treatment history, and adaptive randomization rules are applied within each cohort. The trial also includes multiple correlative studies on tissue, blood, and imaging.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Meeting Abstract Oncology

Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma

Gregory P. Botta et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Eva Versteijne et al.

Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation

Tanios S. Bekaii-Saab et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis

Yuki Homma et al.

Summary: This study found through retrospective data analysis that patients with isolated lung metastasis after pancreatectomy had a better prognosis, and patients who underwent pulmonary resection had a better long-term outcome.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2022)

添加到收藏夹

Editorial Material Oncology

The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain

Christoph Springfeld et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) patients typically have poor prognosis, and even after curative resection, most patients experience disease relapse and ultimately die. However, adjuvant chemotherapy has significantly improved outcomes for patients eligible for surgery. The PREOPANC trial provides evidence supporting neoadjuvant therapy for patients with borderline resectable PDACs, but not for those with resectable tumors.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Surgery

Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy

Shimpei Maeda et al.

Summary: The pathological treatment effect after resection is associated with prognosis for patients with localized pancreatic adenocarcinoma who received neoadjuvant therapy. Patients who received chemoradiotherapy had a better treatment effect compared to those who received chemotherapy alone, although the median overall survival was similar.

SURGERY (2022)

添加到收藏夹

Review Oncology

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Marco H. Hofmann et al.

Summary: KRAS is a frequently mutated oncogene, and there is a need for both allele-specific and pan-KRAS drugs to target a wide range of KRAS mutations and conquer KRAS-driven cancers.

CANCER DISCOVERY (2022)

添加到收藏夹

Editorial Material Oncology

Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma

Nina N. Sanford et al.

JAMA ONCOLOGY (2022)

添加到收藏夹

Review Cell Biology

Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies-From Discovery to Knowledge-Guided Platforms for Better Patient Management

Daniel Schreyer et al.

Summary: Comprehensive molecular landscaping studies offer hope for PDAC patients and reveal advancements in techniques such as minimally invasive liquid biopsies and integrated genomics, enabling early disease detection and personalized treatment.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

添加到收藏夹

Article Surgery

Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)

Junpei Yamaguchi et al.

Summary: This study aimed to clarify the feasibility and survival benefits of neoadjuvant chemotherapy in treating pancreatic cancer. Patients with borderline-resectable pancreatic cancer were randomly assigned to receive FOLFIRINOX or gemcitabine with nab-paclitaxel as neoadjuvant chemotherapy. The results showed that both regimens were well tolerated and achieved a high R0 resection rate, with favorable survival outcomes observed in the intention-to-treat analysis.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Oncology

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma

Philip A. Philip et al.

Summary: KRAS WT PDAC represents 10.7% of PDAC and is enriched with potential pathogenic drivers and better treatment prognosis. Identifying KRAS WT patients can expand therapeutic options in clinical practice.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes

Rosa Klotz et al.

Summary: The background introduces the importance of surgical resection for pancreatic cancer and the frequent occurrence of local recurrence. The author presents a new extended resection technique called TRIANGLE operation, but its postoperative outcome has not been reported yet. By comparing with the matched historic cohorts, the study finds that TRIANGLE procedure does not increase postoperative morbidity and mortality, but it requires longer operation time and causes more blood loss.

HPB (2022)

添加到收藏夹

Article Oncology

Neoadjuvant Therapy for Rectal Cancer

Felipe F. Quezada-Diaz et al.

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2022)

添加到收藏夹

Article Oncology

The Brown University Oncology Group Experience With FOLFOX plus Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318

Rimini Breakstone et al.

Summary: The combination therapy of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-A) shows promising activity and tolerability in patients with advanced pancreatic ductal adenocarcinoma (PDAC), and may serve as an alternative to FOLFIRINOX.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2022)

添加到收藏夹

Article Medicine, General & Internal

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer

J. H. Strickler et al.

Summary: This study evaluated the safety and efficacy of sotorasib in patients with KRAS p.G12C-mutated pancreatic cancer who had previously received treatment. The results showed that sotorasib demonstrated anticancer activity and had an acceptable safety profile in these patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial.

Alfredo Carrato et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

Lilian Schwarz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

Rainer Fietkau et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

Nicholas A. Ullman et al.

Summary: This article summarizes the mechanisms of immunosuppression within the PDAC tumor microenvironment and provides an up-to-date review of completed and ongoing clinical trials using various immunotherapy strategies.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.

Vinod P. Balachandran et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Genetics & Heredity

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

William L. Hwang et al.

Summary: This study provides a high-resolution molecular landscape of pancreatic ductal adenocarcinoma (PDAC) using single-nucleus RNA sequencing and whole-transcriptome digital spatial profiling. It identifies recurrent expression programs in malignant cells and fibroblasts, including a newly identified neural-like progenitor malignant cell program associated with poor prognosis. The study also reveals three multicellular communities with distinct contributions from malignant, fibroblast and immune subtypes. This refined molecular and cellular classification can guide clinical trials and therapeutic targeting for specific cellular phenotypes and multicellular interactions.

NATURE GENETICS (2022)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer

Andrea Cercek et al.

Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas The A021501 Phase 2 Randomized Clinical Trial

Matthew H. G. Katz et al.

Summary: This randomized clinical trial found that treatment with neoadjuvant modified FOLFIRINOX alone was associated with favorable overall survival (OS) in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) compared with treatment with modified FOLFIRINOX plus hypofractionated radiotherapy. Therefore, modified FOLFIRINOX represents a reference regimen in this setting.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

Andrew Dean et al.

Summary: This study investigated the safety and activity of CEND-1 in combination with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. The results showed that CEND-1 had an acceptable safety profile and adverse events similar to nab-paclitaxel and gemcitabine.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)

M.P. Ducreux et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer

Kyaw Z. Thein et al.

Summary: This study conducted a comprehensive analysis of KRAS(G12C) mutations in different types of cancer through liquid biopsy. The results showed that KRAS(G12C) mutations were detected in various cancers, with the highest detection rate in lung cancer.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Surgery

Arterial Resection in Pancreatic Cancer Surgery Effective After a Learning Curve

Martin Loos et al.

Summary: This study investigated the perioperative and long-term outcomes of patients with locally advanced pancreatic cancer (LAPC) after surgical resection at a high-volume center. The results showed that an arterial surgical approach was effective in LAPC with promising long-term survival.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Oncology

Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization

Emma Nolan et al.

Summary: The study demonstrates a pro-tumorigenic activity of neutrophils in the context of radiotherapy. Activated neutrophils enhance tumor cell growth in the lung by promoting regenerative Notch signaling. Additionally, radiation exposure enhances the stemness phenotype of arriving cancer cells. Blocking neutrophil-dependent Notch activation significantly offsets radiation-enhanced metastases.

NATURE CANCER (2022)

添加到收藏夹

Review Oncology

Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

Ashton A. Connor et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest epithelial malignancies, with increasing research over several decades leading to a better understanding of its carcinogenesis and significant progress in genomics and transcriptomics. The inclusion of PDAC data in international pan-cancer analyses has provided further insights, and the study of PDAC evolution and heterogeneity has led to the proposal of an evolutionary model based on genomics studies of human PDAC.

NATURE REVIEWS CANCER (2022)

添加到收藏夹

Article Surgery

Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer

Ulla Klaiber et al.

Summary: In patients undergoing resection after neoadjuvant therapy for initially unresectable PDAC, preoperative CA 19-9 levels, lymph node involvement, metastasis category, and vascular involvement, but not the R status, were independent prognostic factors of overall survival.

ANNALS OF SURGERY (2021)

添加到收藏夹

Article Oncology

Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis

Lingdi Yin et al.

Summary: The study revealed that somatic mutations, CTCs, and ctDNA still exist in patients with PDAC who achieved pCR after NAT, potentially indicating early recurrence and reduced survival. The current regression evaluation system of PDAC needs to be reassessed at a molecular level.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial

R. Fietkau et al.

Summary: This study suggests that surgery to remove the tumor significantly improves survival in patients with initially unresectable pancreatic cancer.

STRAHLENTHERAPIE UND ONKOLOGIE (2021)

添加到收藏夹

Article Surgery

Periarterial divestment in pancreatic cancer surgery

Markus K. Diener et al.

Summary: Periarterial divestment is a technique to clear periarterial soft tissue around peripancreatic visceral arteries during pancreatic surgery, which can prevent the need for arterial resection in borderline and locally advanced pancreatic cancer. It, together with other resection strategies like artery first maneuver and mesenterico-portal venous bypass first, enables tumor resection in locally advanced pancreatic cancer.

SURGERY (2021)

添加到收藏夹

Article Surgery

Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the halo sign and string sign

Joseph R. Habib et al.

Summary: Most patients diagnosed with pancreatic cancer deemed nonoperative candidates can now be considered for operative resection with periadventitial dissection of the SMA, thanks to improved systemic disease control from neoadjuvant chemotherapy. Preoperative imaging is crucial in triaging patients, with the goal of identifying those with encased SMA that can undergo surgical intervention. This approach has expanded operative methods and offers potential for improved outcomes in pancreatic cancer patients with historically limited treatment options.

SURGERY (2021)

添加到收藏夹

Article Oncology

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)

Florian Gebauer et al.

Summary: This is the first clinical study prospectively evaluating the value of multimodality therapy concepts in oligometastatic pancreatic cancer, aiming to compare neoadjuvant chemotherapy followed by resection in patients with hepatic oligometastasis to historic data.

BMC CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Spatially confined sub-tumor microenvironments in pancreatic cancer

Barbara T. Grunwald et al.

Summary: Through large-scale integration of histology-guided regional multiOMICs with clinical data and patient-derived preclinical models, we identified distinct subTMEs in the human pancreatic tumor microenvironment (TME) that are linked to tumor immunity, subtypes, differentiation, and treatment response. Reactive subTMEs rich in coordinated fibroblast communities were immune hot, while matrix-rich deserted subTMEs harbored fewer activated fibroblasts but showed chemoprotective features. These subTMEs originated in fibroblast differentiation trajectories and produced patient-specific heterogeneity tightly linked to malignant biology.

CELL (2021)

添加到收藏夹

Meeting Abstract Oncology

Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

Salah-Eddin Al-Batran et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer et al.

Summary: The RAPIDO trial aimed to reduce systemic relapses in locally advanced rectal cancer through short-course radiotherapy, chemotherapy, and delayed surgery. Results showed a decreased probability of disease-related treatment failure in the experimental group compared to standard care, with diarrhea being the most common adverse event and neurological toxicity being prominent in the standard care group during adjuvant chemotherapy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma

William A. Hall et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial

Davendra P. S. Sohal et al.

Summary: This study aimed to evaluate the 2-year overall survival rate of perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma (PDA), but did not show significant improvement compared to historical data. The 2-year overall survival rates were 47% and 48% for the two treatment arms, demonstrating adequate safety and high resectability rates with perioperative chemotherapy, as well as challenges in quality control for resectability criteria.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma

R. Nicolle et al.

Summary: The study demonstrates that the RNA-based GemPred stratification can predict the benefit of adjuvant gemcitabine in PDAC patients.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Surgery

Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study

Baobao Cai et al.

Summary: The study introduced a technique called sub-adventitial divestment technique (SDT), which aims to remove tumors while preserving arteries during pancreatectomy for pancreatic cancer. Results showed that SDT group had more advanced tumors compared to the standard surgery group, but there was no significant difference in complication rates and in-hospital mortality between the two groups.

LANGENBECKS ARCHIVES OF SURGERY (2021)

添加到收藏夹

Article Oncology

Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer

Marsha Reyngold et al.

Summary: Ablative radiation therapy following multiagent induction therapy for locally advanced pancreatic cancer is associated with durable locoregional tumor control and favorable survival outcomes. Prospective randomized trials in patients with inoperable LAPC are warranted.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann et al.

Summary: The study compared the efficacy and safety of two multidrug induction chemotherapy regimens for locally advanced pancreatic cancer and found that nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX. However, further evidence is needed to determine whether this translates into improved overall survival for patients.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Q. P. Janssen et al.

Summary: The PREOPANC-2 trial compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer, aiming to provide evidence for the optimal neoadjuvant treatment choice in these patients.

BMC CANCER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

Talia Golan et al.

Summary: By analyzing whole genome sequencing data of PDAC patients, HRD-PDAC can be better identified, and patients without BRCA/PALB2 mutations may also benefit from DNA damage response agents.

GASTROENTEROLOGY (2021)

添加到收藏夹

Review Cell Biology

Clinical Impact of Molecular Subtyping of Pancreatic Cancer

Zhou Xu et al.

Summary: Pancreatic ductal adenocarcinoma is a highly lethal malignancy with a high mortality rate. Treatment of pancreatic cancer is challenging due to factors such as genetic mutations, activation of gene signaling pathways, and tumor microenvironment.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

M. Tempero et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Cell Biology

The biological underpinnings of therapeutic resistance in pancreatic cancer

Gregory L. Beatty et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in the United States, with a low survival rate of 10% over 5 years. The disease demonstrates remarkable adaptability and resistance to therapeutic intervention, contributing to its poor prognosis. Recent advances in understanding the biological underpinnings of PDAC have revealed potential vulnerabilities that can be targeted for treatment.

GENES & DEVELOPMENT (2021)

添加到收藏夹

Review Medicine, General & Internal

Pancreatic Cancer: A Review

Wungki Park et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer with increasing incidence each year, resulting in a high percentage of patients being diagnosed with advanced disease. Current cytotoxic therapies for PDAC are moderately effective, emphasizing the importance of multidisciplinary management, comprehensive germline testing, and integrated supportive care for all patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Oncology

Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients

Jakob Kirkegard et al.

Summary: The study found significant intra-observer agreement variations across six different MDT boards for 18 pancreatic cancer patients with two years between the first and second assessment. Overall agreement was moderate for TNM stage and resectability assessment, but low for treatment allocation.

JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Review Surgery

Technical advances in surgery for pancreatic cancer

M. Schneider et al.

Summary: This review summarizes technical advances in surgery for locally advanced pancreatic ductal adenocarcinoma (PDAC), including new approaches like artery-first and uncinate-first methods, as well as techniques for resection and reconstruction to enhance completeness and reduce local recurrence. Advanced surgical techniques provide a toolkit for curative-intent surgery in PDAC, even in cases with arterial or venous involvement, but effects on overall survival still require high-level clinical evidence.

BRITISH JOURNAL OF SURGERY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival

Ulrike Heger et al.

HPB (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer A Phase 1b/2 Pilot Clinical Trial

Gayle S. Jameson et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib plus Gemcitabine for Resected Cancer of the Pancreatic Head A Phase II Randomized Clinical Trial

Ross A. Abrams et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)

添加到收藏夹

Article Oncology

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

Eileen M. O'Reilly et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Genetics & Heredity

Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

Michelle Chan-Seng-Yue et al.

NATURE GENETICS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma

J. Medrano et al.

PANCREATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Article Surgery

Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes? A Single Institution's Experience With 118 Patients

Philippe Bachellier et al.

ANNALS OF SURGERY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society A Synopsis

Takuji Okusaka et al.

PANCREAS (2020)

添加到收藏夹

Article Surgery

Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma

Syed A. Ahmad et al.

ANNALS OF SURGERY (2020)

添加到收藏夹

Article Surgery

Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

Giampaolo Perri et al.

JAMA SURGERY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer

Michelle Barrord et al.

PANCREAS (2020)

添加到收藏夹

Article Oncology

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results

M. Sinn et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Persistent Cancer Cells: The Deadly Survivors

Shensi Shen et al.

CELL (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study

Fuyuhiko Motoi et al.

JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).

Michiaki Unno et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Molecular subtypes of pancreatic cancer

Eric A. Collisson et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Chemotherapy for pancreatic cancer

Christoph Springfeld et al.

PRESSE MEDICALE (2019)

添加到收藏夹

Meeting Abstract Oncology

randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Margaret A. Tempero et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah-Eddin Al-Batran et al.

LANCET (2019)

添加到收藏夹

Article Surgery

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Robert P. Jones et al.

JAMA SURGERY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy

Georgios Kaissis et al.

PLOS ONE (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer

Vincent Bernard et al.

GASTROENTEROLOGY (2019)

添加到收藏夹

Review Oncology

Optimizing the outcomes of pancreatic cancer surgery

Oliver Strobel et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma

Rebecca L. Porter et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹

Article Oncology

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

Fuyuhiko Motoi et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Adjuvant treatment for pancreatic cancer

Ulla Klaiber et al.

TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017

Shuji Isaji et al.

PANCREATOLOGY (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on

Caroline Verbeke et al.

PANCREATOLOGY (2018)

添加到收藏夹

Article Oncology

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

Christoph Heining et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial

Janet E. Murphy et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer

Aoi Hayasaki et al.

CANCERS (2018)

添加到收藏夹

Article Oncology

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Lilian Schwarz et al.

BMC CANCER (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It

Sjors Klompmaker et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2018)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

Kyaw L. Aung et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Surgery

Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma

Vincent P. Groot et al.

ANNALS OF SURGERY (2018)

添加到收藏夹

Article Oncology

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

Marianne Sinn et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos et al.

LANCET (2017)

添加到收藏夹

Article Surgery

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial-1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial

Knut Jorgen Labori et al.

BMC SURGERY (2017)

添加到收藏夹

Article Oncology

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

K. Allenson et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Radical surgery of oligometastatic pancreatic cancer

T. Hackert et al.

EJSO (2017)

添加到收藏夹

Article Surgery

Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients

Thilo Hackert et al.

ANNALS OF SURGERY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice

Lena Seifert et al.

GASTROENTEROLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial

Pascal Hammel et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka et al.

LANCET (2016)

添加到收藏夹

Review Oncology

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

Mustafa Suker et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic analyses identify molecular subtypes of pancreatic cancer

Peter Bailey et al.

NATURE (2016)

添加到收藏夹

Article Surgery

Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis

Michael Tachezy et al.

SURGERY (2016)

添加到收藏夹

Article Surgery

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101

Matthew H. G. Katz et al.

JAMA SURGERY (2016)

添加到收藏夹

Article Surgery

Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer

Cristina R. Ferrone et al.

ANNALS OF SURGERY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets

Riccardo Casadei et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2015)

添加到收藏夹

Article Genetics & Heredity

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

Richard A. Moffitt et al.

NATURE GENETICS (2015)

添加到收藏夹

Article Oncology

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer

Henriette Golcher et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2015)

添加到收藏夹

Article Oncology

Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

Juan W. Valle et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

William Greenhalf et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

添加到收藏夹

Article Surgery

When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery

Horacio J. Asbun et al.

SURGERY (2014)

添加到收藏夹

Article Oncology

CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy

Werner Hartwig et al.

ANNALS OF SURGICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

Matthew H. G. Katz et al.

ANNALS OF SURGICAL ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

Helmut Oettle et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Article Oncology

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

Somnath Mukherjee et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Surgery

Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer

Akimasa Nakao et al.

ANNALS OF SURGERY (2012)

添加到收藏夹

Article Oncology

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

Michele Reni et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)

添加到收藏夹

Article Oncology

Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma

Jan Schmidt et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial

Matthew H. G. Katz et al.

ANNALS OF SURGICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial

William F. Regine et al.

ANNALS OF SURGICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

Stefan Heinrich et al.

BMC CANCER (2011)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sreenath V. Sharma et al.

CELL (2010)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial

John P. Neoptolemos et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)

添加到收藏夹

Editorial Material Oncology

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

Mark P. Callery et al.

ANNALS OF SURGICAL ONCOLOGY (2009)

添加到收藏夹

Article Oncology

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

H. Ueno et al.

BRITISH JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

David Cunningham et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial

William F. Regine et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)

添加到收藏夹

Article Surgery

Borderline resectable pancreatic cancer: The importance of this emerging stage of disease

Matthew H. G. Katz et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial

Helmut Oettle et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)

添加到收藏夹

Article Oncology

Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy

Gauri R. Varadhachary et al.

ANNALS OF SURGICAL ONCOLOGY (2006)

添加到收藏夹

Article Medicine, General & Internal

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

David Cunningham et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

Article Gastroenterology & Hepatology

Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer

HG Smeenk et al.

DIGESTIVE SURGERY (2005)

添加到收藏夹

Article Medicine, General & Internal

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

JP Neoptolemos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

Article Oncology

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma

T Takada et al.

CANCER (2002)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:: a randomised controlled trial

JP Neoptolemos et al.

LANCET (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.